Eisai

Amyloid-Beta Structure Revelation Sheds Light on Leqembi’s Function
Amyloid-Beta Structure Revelation Sheds Light on Leqembi’s Function
BioSpace
Eisai
Biogen
Alzheimer's disease
Leqembi
amyloid beta
Flag link:
JAMA: Leqembi could cost Medicare up to $5B per year
JAMA: Leqembi could cost Medicare up to $5B per year
Medical Marketing and Media
Biogen
Eisai
Leqembi
drug pricing
Medicare
Alzheimer's disease
JAMA
Flag link:
Eisai Pays up to $2B for ADC Bearing Its Halaven as Payload
Eisai Pays up to $2B for ADC Bearing Its Halaven as Payload
BioSpace
Eisai
Bliss Biopharmaceutical
clinical trials
antibody-drug conjugate
Halaven
Flag link:
Merck/Eisai Drops Melanoma Program for Keytruda-Lenvima Combo After Phase III Fail
Merck/Eisai Drops Melanoma Program for Keytruda-Lenvima Combo After Phase III Fail
BioSpace
Merck
Keytruda
Eisai
Lenvima
melanoma
clinical trials
cancer
colorectal cancer
Flag link:
Despite CMS snub, Eisai is 'not so nervous' about Leqembi's long-term coverage prospects: US CEO
Despite CMS snub, Eisai is 'not so nervous' about Leqembi's long-term coverage prospects: US CEO
Fierce Pharma
Eisai
Leqembi
FDA
CMS
Alzheimer's disease
Flag link:
Alzheimer's Association campaigns for broader Leqembi coverage: report
Alzheimer's Association campaigns for broader Leqembi coverage: report
Fierce Pharma
CMS
Eisai
Biogen
Leqembi
Alzheimer's disease
Flag link:
VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm
VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm
Endpoints
VHA
Eisai
Biogen
Leqembi
Aduhelm
Alzheimer's disease
Flag link:
Eisai projects $7B in sales by 2030 for new Alzheimer's drug
Eisai projects $7B in sales by 2030 for new Alzheimer's drug
Endpoints
Eisai
Biogen
Alzheimer's disease
Leqembi
Flag link:
FDA sets July decision date for full approval of Leqembi
FDA sets July decision date for full approval of Leqembi
BioSpace
Eisai
Biogen
Alzheimer's disease
Leqembi
FDA
lecanemab
Flag link:
ICER dials up recommended price range for Eisai's Leqembi—but still calls for sizable discount
ICER dials up recommended price range for Eisai's Leqembi—but still calls for sizable discount
Fierce Pharma
ICER
Eisai
Leqembi
drug pricing
Alzheimer's disease
Flag link:
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Clinical Trials Arena
Alzheimer's disease
Biogen
Eisai
Lundbeck
Otsuka
Avanir Pharmaceuticals
Axesome
Aduhelm
Leqembi
Flag link:
Medicare maintains limits on Eisai’s new Alzheimer’s drug
Medicare maintains limits on Eisai’s new Alzheimer’s drug
BioPharma Dive
Medicare
CMS
Eisai
Biogen
Leqembi
Alzheimer's disease
Flag link:
Eisai Anticipates Full Approval of Leqembi as Early as July
Eisai Anticipates Full Approval of Leqembi as Early as July
BioSpace
Eisai
FDA
Alzheimer's disease
Leqembi
lecanemab
Flag link:
BioSpace Layoff Tracker 2023: Grifols, Frequency, Eliem and More Cut Staff
BioSpace Layoff Tracker 2023: Grifols, Frequency, Eliem and More Cut Staff
BioSpace
layoffs
Grifols
Frequency Therapeutics
Eliem Therapeutics
Aligos Therapeutics
Thermo Fisher Scientific
Magenta Therapeutics
Eisai
Amgen
Y-mAbs Therapeutics
Century Therapeutics
Elevation Oncology
Calithera Biosciences
Editas Medicine
Verily
Abzena
Flag link:
Eisai gives first glimpse into Alzheimer’s drug launch
Eisai gives first glimpse into Alzheimer’s drug launch
BioPharma Dive
Eisai
Alzheimer's disease
drug launches
Leqembi
Flag link:
With all eyes on new Alzheimer's med, Eisai lays off 91 staffers on its Fycompa team
With all eyes on new Alzheimer's med, Eisai lays off 91 staffers on its Fycompa team
Fierce Pharma
Eisai
Fycompa
layoffs
Flag link:
Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval
Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval
Motley Fool
Biogen
Eisai
Alzheimer's disease
Leqembi
lecanemab
Flag link:
Alzheimer’s disease trials: How does Lilly’s donanemab compare to lecanemab?
Alzheimer’s disease trials: How does Lilly’s donanemab compare to lecanemab?
Clinical Trials Arena
clinical trials
Alzheimer's disease
Eisai
Biogen
Eli Lilly
Leqembi
lecanemab
donanemab
Flag link:
After FDA nod, Eisai and Biogen file lecanemab in EU
After FDA nod, Eisai and Biogen file lecanemab in EU
Pharmaphorum
Eisai
Biogen
lecanemab
Europe
Alzheimer's disease
Flag link:
Eisai learns from Biogen’s Aduhelm disaster
Eisai learns from Biogen’s Aduhelm disaster
EP Vantage
Eisai
Biogen
Leqembi
Aduhelm
Alzheimer's disease
drug pricing
Flag link:

Pages